10 High Growth Forever Dividend Stocks To Invest In

3. Eli Lilly and Company (NYSE:LLY)

5-Year Revenue Growth: 15.08%

Eli Lilly and Company (NYSE:LLY) is an American multinational pharmaceutical company that offers a wide range of related services and products. The GLP-1 agonist market appears to be entering a transformative phase, presenting Eli Lilly with a significant opportunity to strengthen its position over the next year. Industry analysts project that annual sales for these in-demand treatments could reach as much as $150 billion by 2030. Currently, the space is largely controlled by just two major players—Novo Nordisk and Eli Lilly. According to estimates from Novo Nordisk, Eli Lilly currently holds about 34% of the market share.

One of the key treatments drawing investor attention this year is orforglipron, an oral, once-daily drug under development by Eli Lilly and Company (NYSE:LLY) for weight management and related health conditions. While initial trial results have been encouraging, the upcoming findings from phase 3 trials—due in the near future—will play a pivotal role in shaping the drug’s path toward potential regulatory approval.

Eli Lilly and Company (NYSE:LLY) is expected to publish data from several late-stage studies throughout the year, evaluating orforglipron’s impact on conditions such as diabetes, obesity, and sleep apnea. The first of these trials is anticipated to conclude in April.

Eli Lilly and Company (NYSE:LLY) is one of the best high growth dividend stocks as the company has raised its payouts for 11 years in a row. In addition, the company has never missed a dividend in 139 years. Its quarterly dividend currently sits at $1.50 per share for a dividend yield of 0.82%, as recorded on April 13.